{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:15:45Z","timestamp":1794885345054,"version":"4.9.1"},"reference-count":46,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":603,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2000,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Aim<\/jats:bold>\n                    :\u2003To determine the efficacy and tolerability of sibutramine hydrochloride in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    :\u2003This study was a 24\u2010week, double\u2010blind, multicentre trial following a 5\u2010week placebo run\u2010in period. One hundred and seventy\u2010five obese (body mass index (b.m.i.) \u226527\u2003kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n\u2003=\u200389; mean age 53.5\u2003years; mean weight 99.3\u2003kg) or placebo (n\u2003=\u200386; mean age 55\u2003years; mean weight 98.2\u2003kg) at 16 participating centres. To achieve moderate calorie restriction (deficit\u2003\u2265\u2003250\u2013500 kcal\/day), individual dietary counselling was accompanied by either placebo or sibutramine (initial dosage of 5\u2003mg\/day titrated up by 5\u2003mg biweekly through week 6, and maintained at 20\u2003mg through week 24). The main outcome measures included changes in weight, b.m.i., waist and hip circumference, glycaemic control, lipid profile, and quality of life, and evaluation of reported adverse events.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    :\u2003Sixty\u2010seven per cent of sibutramine patients and 71% of placebo patients completed the study. At week 24 when comparing those who completed the course, sibutramine compared with placebo patients showed significantly greater (p\u2003&lt;\u20030.001) absolute (\u22124.3 vs. \u22120.4\u2003kg) and percentage (\u22124.5% vs. \u22120.5%) weight loss. Weight loss \u22655% or 10% was achieved by 33% and 8% of sibutramine patients, respectively, but no placebo patients (p\u2003&lt;\u20030.03 or better). Improvement in glycaemic control was correlated with weight loss (p\u2003&lt;\u20030.001). In 5% and 10% weight\u2010loss responders, mean treatment differences were \u22120.53% and \u22121.65% (p\u2003\u2264\u20030.05), respectively, for HbA\n                    <jats:sub>1c<\/jats:sub>\n                    , and \u22121.4\u2003mmol\/l (p \u22640.05) and \u22123.8 (p \u22640.05) mmol\/l for fasting plasma glucose. Sibutramine patients also showed improvements in fasting insulin, triglycerides, HDL cholesterol, and quality\u2010of\u2010life assessments. Overall, sibutramine was well tolerated compared with the placebo. Sibutramine treatment was associated with small mean increases in blood pressure (BP) and pulse, although an increase in BP was not seen in sibutramine\u2010treated patients who lost\u2003\u2265\u20035% of their weight.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    :\u2003Sibutramine produced statistically and clinically significant weight loss when used in combination with recommendations for moderate caloric restriction. This weight loss was associated with improvements in metabolic control and quality of life, and sibutramine was generally well tolerated in obese patients with type 2 diabetes.\n                  <\/jats:p>","DOI":"10.1046\/j.1463-1326.2000.00081.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T05:28:38Z","timestamp":1027661318000},"page":"175-187","source":"Crossref","is-referenced-by-count":191,"title":["Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus"],"prefix":"10.1111","volume":"2","author":[{"given":"K.","family":"Fujioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. B.","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. E.","family":"Lebovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"The Sibutramine\/Diabetes Clinical Study","family":"Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.4.518"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"C11","DOI":"10.2337\/diacare.21.3.C11","article-title":"Diabetes in America: epidemiology and scope of the problem","volume":"21","author":"Harris MI.","year":"1998","journal-title":"Diabetes Care"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1744"},{"key":"e_1_2_6_5_2","first-page":"335","article-title":"Weight control: metabolic and cardiovascular effects","volume":"3","author":"Albu J","year":"1995","journal-title":"Diabetes Rev"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370100063012"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.17.5.490"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.3.350"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1992.tb01756.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1995.tb00504.x"},{"key":"e_1_2_6_11_2","first-page":"387P","article-title":"Effects in the rat of sibutramine on food intake and the behavioural satiety sequence [abstract]","volume":"114","author":"Halford JCG","year":"1994","journal-title":"Br J Pharmacol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(89)90048-8"},{"key":"e_1_2_6_13_2","first-page":"S18","article-title":"Sibutramine: a novel anti\u2010obesity drug. A review of the pharmacological evidence to differentiate it from d\u2010amphetamine and d\u2010fenfluramine","volume":"22","author":"Heal DJ","year":"1998","journal-title":"Int J Obes"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244604"},{"key":"e_1_2_6_15_2","first-page":"A308","article-title":"Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus [abstract]","volume":"48","author":"Heath MJ","year":"1999","journal-title":"Diabetes"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00411-2"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800540"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00701.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.28.12.1039"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1995.tb00120.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/52.3-4.591"},{"key":"e_1_2_6_23_2","volume-title":"Contributions to Probability and Statistics: Essays in Honor of Harold Hotelling. Stanford, CA.","author":"Olkin I","year":"1960"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2307\/1402373"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.6.896"},{"key":"e_1_2_6_26_2","first-page":"51S","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report","volume":"6","author":"National Institutes of Health.","year":"1998","journal-title":"Obes Res"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-79-3-425"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90676-9"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856060-00019"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.35.2.155"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.148.4.873"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.10.5.563"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.8.1288"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(90)90299-R"},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1989.03430030048032","article-title":"Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey","volume":"262","author":"Stern MP","year":"1989","journal-title":"JAMA"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265546"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.30.2.S82"},{"key":"e_1_2_6_38_2","doi-asserted-by":"crossref","first-page":"C39","DOI":"10.2337\/diacare.21.3.C39","article-title":"Relation of glycemic control to diabetic complications and health outcomes","volume":"21","author":"Klein R","year":"1998","journal-title":"Diabetes Care"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.235"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11509-4"},{"key":"e_1_2_6_41_2","first-page":"65","article-title":"A single\u2010dose, placebo\u2010controlled, comparative evaluation of the cardiovascular effects of sibutramine and amitriptyline in normal volunteers","volume":"11","author":"Wynne RD","year":"1997","journal-title":"Int J Pharmaceut Med"},{"key":"e_1_2_6_42_2","first-page":"240A","article-title":"Fluoxetine in obese patients with noninsulin\u2010dependent diabetes mellitus [abstract]","volume":"40","author":"Goldstein DJ","year":"1992","journal-title":"Clin Res"},{"key":"e_1_2_6_43_2","first-page":"717]","article-title":"Fluoxetine treatment of the obese diabetic","volume":"16","author":"Gray DS","year":"1992","journal-title":"Int J Obes Relat Metab Disord 1992; 16: 193\u2013198.[Published Erratum Appears in Int J Obes Relat Metab Disord"},{"key":"e_1_2_6_44_2","first-page":"41","article-title":"Sibutramine in the treatment of overweight non\u2010insulin dependent diabetics [abstract O72]","volume":"19","author":"Griffiths J","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_6_45_2","first-page":"144","article-title":"Body composition changes following weight loss induced by sibutramine [abstract P395]","volume":"19","author":"Griffiths J","year":"1995","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_6_46_2","first-page":"A353","article-title":"Sibutramine reduces visceral fat, leptin, and estradiol level in obese women","volume":"12","author":"Yip I","year":"1998","journal-title":"FASEB"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.11.2.103"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1463-1326.2000.00081.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1046\/j.1463-1326.2000.00081.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:25:38Z","timestamp":1761881138000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1046\/j.1463-1326.2000.00081.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["10.1046\/j.1463-1326.2000.00081.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1463-1326.2000.00081.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}